AbbVie Acquires Apogee Therapeutics for $10.9 Billion in Cash

SentiSense · Published · Updated

AbbVie has acquired Apogee Therapeutics for $10.9 billion in cash, expanding its immunology pipeline. The deal aims to bolster AbbVie's position in th...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis